Top

Published in:

01-12-2016 | Review

The growing world of CAR T cell trials: a systematic review

Authors: Astrid Holzinger, Markus Barden, Hinrich Abken

Published in: Cancer Immunology, Immunotherapy | Issue 12/2016

Abstract

In recent years, cancer treatment involving adoptive cell therapy with chimeric antigen receptor (CAR)-modified patient’s immune cells has attracted growing interest. Using gene transfer techniques, the patient’s T cells are modified ex vivo with a CAR which redirects the T cells toward the cancer cells through an antibody-derived binding domain. The T cells are activated by the CAR primary signaling and costimulatory domains. Such “second generation” CAR T cells induced complete remission of B cell malignancies in the long-term. In this fast-moving field with a growing number of engineered T cell products, we list about 100 currently ongoing trials here that involve CAR T cells targeting hematopoietic malignancies and solid cancer. Major challenges in the further development of the therapy are briefly discussed.

Eshhar Z (2008) The T-body approach: redirecting T cells with antibody specificity. Handb Exp Pharmacol 181:329–342. doi:10.1007/978-3-540-73259-4_14 CrossRef

Finney HM, Lawson AD, Bebbington CR, Weir AN (1998) Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 161:2791–2797PubMed

Hombach A, Wieczarkowiecz A, Marquardt T et al (2001) Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol 167:6123–6131CrossRefPubMed

Chmielewski M, Kopecky C, Hombach AA, Abken H (2011) IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res 71:5697–5706CrossRefPubMed

Maude SL, Frey N, Shaw PA et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371:1507–1517. doi:10.1056/NEJMoa1407222 CrossRefPubMedPubMedCentral

Singh N, Frey NV, Grupp SA, Maude SL (2016) CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia. Curr Treat Options Oncol 17:28. doi:10.1007/s11864-016-0406-4 CrossRefPubMed

Savoldo B, Ramos CA, Liu E et al (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Investig 121:1822–1826. doi:10.1172/JCI46110 CrossRefPubMedPubMedCentral

Cruz CRY, Micklethwaite KP, Savoldo B et al (2013) Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 122:2965–2973. doi:10.1182/blood-2013-06-506741 CrossRefPubMedPubMedCentral

Xu X-J, Zhao H-Z, Tang Y-M (2013) Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials. Leuk Lymphoma 54:255–260. doi:10.3109/10428194.2012.715350 CrossRefPubMed

10.

Zhang T, Cao L, Xie J et al (2015) Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis. Oncotarget 6:33961–33971. doi:10.18632/oncotarget.5582 PubMedPubMedCentral

11.

Kalos M, Levine BL, Porter DL et al (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3:95ra73. doi:10.1126/scitranslmed.3002842 CrossRefPubMedPubMedCentral

12.

Porter DL, Levine BL, Kalos M et al (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725–733. doi:10.1056/NEJMoa1103849 CrossRefPubMedPubMedCentral

13.

Porter DL, Hwang W-T, Frey NV et al (2015) Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 7:303ra139. doi:10.1126/scitranslmed.aac5415 CrossRefPubMed

14.

Brentjens RJ, Rivière I, Park JH et al (2011) Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118:4817–4828. doi:10.1182/blood-2011-04-348540 CrossRefPubMedPubMedCentral

15.

Kochenderfer JN, Dudley ME, Feldman SA et al (2012) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119:2709–2720. doi:10.1182/blood-2011-10-384388 CrossRefPubMedPubMedCentral

16.

Davila ML, Bouhassira DCG, Park JH et al (2014) Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int J Hematol 99:361–371. doi:10.1007/s12185-013-1479-5 CrossRefPubMed

17.

Lee DW, Kochenderfer JN, Stetler-Stevenson M et al (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385:517–528. doi:10.1016/S0140-6736(14)61403-3 CrossRefPubMed

18.

Morgan RA, Yang JC, Kitano M et al (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18:843–851. doi:10.1038/mt.2010.24 CrossRefPubMedPubMedCentral

19.

Ahmed N, Brawley VS, Hegde M et al (2015) Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol 33:1688–1696. doi:10.1200/JCO.2014.58.0225 CrossRefPubMedPubMedCentral

20.

Gross G, Eshhar Z (2016) Therapeutic potential of T cell chimeric antigen receptors (CARs) in cancer treatment: counteracting off-tumor toxicities for safe CAR T cell therapy. Annu Rev Pharmacol Toxicol 56:59–83. doi:10.1146/annurev-pharmtox-010814-124844 CrossRefPubMed

21.

Fedorov VD, Themeli M, Sadelain M (2013) PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med 5:215ra172. doi:10.1126/scitranslmed.3006597 CrossRefPubMedPubMedCentral

22.

Kloss CC, Condomines M, Cartellieri M et al (2012) Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 31:71–75. doi:10.1038/nbt.2459 CrossRefPubMed

23.

Beatty GL, Haas AR, Maus MV et al (2014) Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2:112–120. doi:10.1158/2326-6066.CIR-13-0170 CrossRefPubMed

24.

Brentjens R, Yeh R, Bernal Y et al (2010) Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 18:666–668. doi:10.1038/mt.2010.31 CrossRefPubMedPubMedCentral

25.

Grupp SA, Kalos M, Barrett D et al (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368:1509–1518. doi:10.1056/NEJMoa1215134 CrossRefPubMedPubMedCentral

26.

Chen F, Teachey DT, Pequignot E et al (2016) Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. J Immunol Methods 434:1–8. doi:10.1016/j.jim.2016.03.005 CrossRefPubMed

27.

Davila ML, Riviere I, Wang X et al (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6:224ra25. doi:10.1126/scitranslmed.3008226 CrossRefPubMedPubMedCentral

28.

Maude SL, Barrett D, Teachey DT, Grupp SA (2014) Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 20:119–122. doi:10.1097/PPO.0000000000000035 CrossRefPubMedPubMedCentral

29.

Teachey DT, Lacey SF, Shaw PA et al (2016) Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 6:664–679. doi:10.1158/2159-8290.CD-16-0040 CrossRefPubMed

30.

Katz SC, Burga RA, McCormack E et al (2015) Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified t-cell therapy for CEA + Liver Metastases. Clin Cancer Res 21:3149–3159. doi:10.1158/1078-0432.CCR-14-1421 CrossRefPubMedPubMedCentral

31.

Xu Y, Zhang M, Ramos CA et al (2014) Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123:3750–3759. doi:10.1182/blood-2014-01-552174 CrossRefPubMedPubMedCentral

32.

Abken H (2015) Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors. Immunotherapy 7:535–544. doi:10.2217/imt.15.15 CrossRefPubMed

33.

Kobold S, Grassmann S, Chaloupka M et al (2015) Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy. J Natl Cancer Inst. doi:10.1093/jnci/djv146 PubMedCentral

34.

Kawalekar OU, O’Connor RS, Fraietta JA et al (2016) Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44:380–390. doi:10.1016/j.immuni.2016.01.021 CrossRefPubMed

35.

Kochenderfer JN, Wilson WH, Janik JE et al (2010) Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116:4099–4102. doi:10.1182/blood-2010-04-281931 CrossRefPubMedPubMedCentral

36.

Kochenderfer JN, Dudley ME, Kassim SH et al (2015) Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33:540–549. doi:10.1200/JCO.2014.56.2025 CrossRefPubMed

37.

Kochenderfer JN, Dudley ME, Carpenter RO et al (2013) Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122:4129–4139. doi:10.1182/blood-2013-08-519413 CrossRefPubMedPubMedCentral

38.

Brentjens RJ, Davila ML, Riviere I et al (2013) CD19-targeted t cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5:177ra38. doi:10.1126/scitranslmed.3005930 CrossRefPubMedPubMedCentral

39.

Garfall AL, Maus MV, Hwang W-T et al (2015) Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med 373:1040–1047. doi:10.1056/NEJMoa1504542 CrossRefPubMedPubMedCentral

40.

Till BG, Jensen MC, Wang J et al (2012) CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119:3940–3950. doi:10.1182/blood-2011-10-387969 CrossRefPubMedPubMedCentral

41.

Wang Q, Wang Y, Lv H et al (2015) Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther 23:184–191. doi:10.1038/mt.2014.164 PubMed

42.

Ritchie DS, Neeson PJ, Khot A et al (2013) Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther 21:2122–2129. doi:10.1038/mt.2013.154 CrossRefPubMedPubMedCentral

43.

van Schalkwyk MCI, Papa SE, Jeannon J-P et al (2013) Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer. Hum Gene Ther Clin Dev 24:134–142. doi:10.1089/humc.2013.144 CrossRefPubMed

44.

Morgan RA, Johnson LA, Davis JL et al (2012) Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther 23:1043–1053. doi:10.1089/hum.2012.041 CrossRefPubMedPubMedCentral

45.

Maus MV, Haas AR, Beatty GL et al (2013) T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 1:26–31. doi:10.1158/2326-6066.CIR-13-0006 CrossRefPubMedCentral

46.

You F, Jiang L, Zhang B et al (2016) Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells. Sci China Life Sci. 59:386–397. doi:10.1007/s11427-016-5024-7 CrossRefPubMed

Title: The growing world of CAR T cell trials: a systematic review
Authors: Astrid Holzinger
Markus Barden
Hinrich Abken
Publication date: 01-12-2016
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 12/2016
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-016-1895-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2016

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

Killer immunoglobulin-like receptor (KIR) and KIR–ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2

Surface biotinylation of cytotoxic T lymphocytes for in vivo tracking of tumor immunotherapy in murine models

Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells

Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer

Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models

Keynote webinar | Spotlight on antibody–drug conjugates in cancer